Table 2.
Predicted target information of GTs.
| ID | Target | Number of Compounds | Gene Name | Possibly Relevant Diseases |
|---|---|---|---|---|
| 1 | CYP2C9 | 8 | CYP2C9 | ADMET |
| 2 | CDK2 | 6 | CDK2 | cancer |
| 3 | GCN5 | 6 | KAT2A | cancer |
| 4 | PPAR γ | 5 | PPARG | obesity |
| 5 | COX1 | 5 | PTGS1 | pain, cardiovascular diseases |
| 6 | MEK1 | 5 | MAP2K1 | cancer |
| 7 | CYP3A4 | 5 | CYP A4 | ADMET |
| 8 | 11beta-HSD 1 | 5 | HSD11B1 | diabetes, obesity |
| 9 | PDE5A | 5 | PDE 5A | cardiovascular diseases |
| 10 | PTP1B | 4 | PTPN1 | diabetes, obesity |
| 11 | Syk | 4 | Syk | cancer |
| 12 | Lck | 4 | Lck | autoimmune suppression |
| 13 | c-Met | 4 | MET | cancer |
| 14 | Chk1 | 4 | Chk1 | cancer |
| 15 | Pim-1 | 4 | Pim-1 | cancer |
| 16 | CDK5 | 3 | CDK5 | cognitive defects, cancer |
| 17 | COX2 | 2 | Ptgs2 | pain, inflammation |
| 18 | FXR | 2 | NR1H4 | ADMET, bile acid-induced hepatotoxicity |
| 19 | FGFR1 | 2 | FGFR1 | diabetic retinopathy, cardiovascular diseases, cancer |